Table 5.

Comparison of groups with primary IOL explant and deferred IOL explant

	Primary IOL explant	Delayed IOL explant	P value for difference	95% CI for difference
Number of eyes	25	52	0.32
Males	14 (56.36%)	23 (44.23%)	0.07
Mean age	54.09±14.9	58±15.02	0.16
Following trauma	2 (9.09%)	3 (5.76%)	0.59
Following cataract surgery	17 (68%)	44 (84.61%)	0.09
Following endogenous spread	2 (50%)	2 (50%)	1
Following noncataract surgery	2 (28.57%)	71.42%)	0.12
Vision at presentation (>20/400)	2 (7.27%)	14 (27%)	0.04	0.14% to 34.1%
Time to IOL explant in days from presentation	0	88.11±66.58 Median 70	<0.0001	61.49 to 114.72
Significant corneal haze at presentation	12 (47.27%)	21 (40.38%)	0.33
Interval between inciting event and endophthalmitis (days)	268.07±759.02 (Median 78)	198.44±603.84 (Median 80)	0.99
Interval between onset of symptoms to presentation (days)	6±2.75 (Median 8)	6.84±2.31 (Median 8)	0.09
Number of repeat intravitreal antibiotic injections required	0.58±0.86 (Median 0)	2.62±1.78 (Median 2)	<0.0001	2.00 to 2.22
Days to resolution after IOL explant	35.16±14.26 (Median 32)	55.5±8.24 (Median 56.5)	<0.0001	15.22 to 25.45
Total follow-up (months)	28.31±46.97 (Median 5.5)	21.03±37.27 (Median 7)	0.8
Retinal detachment in follow-up	0 (0%)	3 (5.76%)	0.07
Corneal decompensation in follow-up	6 (24%)	8 (15.38%)	0.28
Phthisis bulbi	2 (8%)	2 (3.84%)	0.44
Neovascular glaucoma	1 (4%)	0	0.14
Culture positive cases	9 (36%)	28 (53.84%)	0.14
Favorable vision at last follow-up	8 (32%)	20 (38.46%)	0.58